Back to top
more

Kenvue Inc. (KVUE)

(Real Time Quote from BATS)

$21.70 USD

21.70
13,051,892

+0.26 (1.21%)

Updated Aug 7, 2025 12:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (183 out of 246)

Industry: Consumer Products - Staples

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Kenvue (KVUE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Kenvue (KVUE) Q2 Earnings Top Estimates

by Zacks Equity Research

Kenvue (KVUE) delivered earnings and revenue surprises of +3.57% and -0.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Edgewell Personal Care (EPC) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Edgewell Personal (EPC) delivered earnings and revenue surprises of -8.91% and -4.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Countdown to Kenvue (KVUE) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top-and-bottom-line estimates for Kenvue (KVUE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Zacks Equity Research

Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

by Kinjel Shah

JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.

Zacks Equity Research

JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise

by Zacks Equity Research

JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.

Zacks Equity Research

Company News for Jul 15, 2025

by Zacks Equity Research

Companies in The News Are: FAST,COIN,KVUE,RIOT

Kinjel Shah headshot

Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?

by Kinjel Shah

JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.

Kinjel Shah headshot

J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

by Kinjel Shah

JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.

Kinjel Shah headshot

JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges

by Kinjel Shah

While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern

Zacks Equity Research

Compared to Estimates, Kenvue (KVUE) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Kenvue (KVUE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Kenvue (KVUE) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Kenvue (KVUE) delivered earnings and revenue surprises of 9.09% and 1.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Edgewell Personal Care (EPC) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Edgewell Personal (EPC) delivered earnings and revenue surprises of -3.33% and 1.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ahead of Kenvue (KVUE) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Kenvue (KVUE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.

Zacks Equity Research

Kenvue (KVUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Kenvue (KVUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Here's How You Should Play JNJ Stock After Q1 Earnings Beat

by Kinjel Shah

Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.

Zacks Equity Research

JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal

by Zacks Equity Research

J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.

Kinjel Shah headshot

Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings

by Kinjel Shah

JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.

Kinjel Shah headshot

Here's How to Play JNJ Stock as it Announces $55B US Investment Plan

by Kinjel Shah

Those who own JNJ stock may stay invested for some time, as the company is optimistic about a better performance in 2025.

Kinjel Shah headshot

J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?

by Kinjel Shah

Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.

Zacks Equity Research

Kenvue (KVUE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Kenvue (KVUE) Q4 Earnings Meet Estimates

by Zacks Equity Research

Kenvue (KVUE) delivered earnings and revenue surprises of 0% and 2.94%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hershey's Q4 Earnings Release on Deck: What to Expect From HSY?

by Zacks Equity Research

HSY's Q4 results are likely to reflect gains from pricing and brand strength amid cost inflation and a tough consumer landscape.

Zacks Equity Research

Newell to Report Q4 Earnings: What Surprise Awaits Investors?

by Zacks Equity Research

NWL's fourth-quarter 2024 bottom-line results are likely to reflect the impacts of a tough macroeconomic environment, including inflation.